[{"id":"1f15ecc0-8deb-4e48-8468-0cba146fe8fd","acronym":"","url":"https://clinicaltrials.gov/study/NCT05181865","created_at":"2022-01-06T22:53:46.024Z","updated_at":"2024-07-02T16:36:17.525Z","phase":"Phase 1/2","brief_title":"Phase 1/2a Study to Evaluate FL-301 in Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT05181865","lead_sponsor":"Flame Biosciences","biomarkers":" CLDN18","pipe":" | ","alterations":" CLDN1 positive","tags":["CLDN18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CLDN1 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FL-301"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 01/01/2022","start_date":" 01/01/2022","primary_txt":" Primary completion: 01/18/2022","primary_completion_date":" 01/18/2022","study_txt":" Completion: 01/18/2022","study_completion_date":" 01/18/2022","last_update_posted":"2022-02-07"},{"id":"292d4ffb-ecae-4cd5-972e-7dd41267ba78","acronym":"NBL-015-CSP-001","url":"https://clinicaltrials.gov/study/NCT05153096","created_at":"2021-12-10T23:53:26.455Z","updated_at":"2024-07-02T16:36:18.991Z","phase":"Phase 1","brief_title":"Evaluation of the Safety and Efficacy of NBL-015 in Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT05153096 - NBL-015-CSP-001","lead_sponsor":"NovaRock Biotherapeutics, Ltd","biomarkers":" CLDN18","pipe":"","alterations":" ","tags":["CLDN18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FL-301"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 410","initiation":"Initiation: 04/01/2022","start_date":" 04/01/2022","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2021-12-31"}]